Extraido de Europace Mayo 2011
Sleep apnoea (SA) is a common but under-diagnosed breathing disorderthat is associated with increases in cardiovascular morbidityand mortality, cardiac arrhythmias, and daytime sleepiness.1–6 Bothcentral sleep apnoea (CSA) and obstructive sleep apnoea (OSA)are common problems among symptomatic congestive heartfailure (CHF) patients, which has caused some authors to proposethat all CHF patients should undergo a sleep study.
In this groupof patients, SA increases overnight sympathetic activity, decreasesoxygen delivery, and has a negative effect on physical mobility.8,9Evidence has shown that cardiac resynchronization therapy(CRT) reduces the morbidity and mortality associated with symptomaticCHF.10 Current guidelines10,11 recommend that CRT beoffered to patients with a left ventricular ejection fraction (LVEF)of ≤35%, a wide QRS complex (≥120 ms) and left ventriculardilatation. Many recent studies12 – 20 have demonstrated the positiveeffect that CRT has on the Apnoea2Hypopnoea Index(AHI¼a measure of SA severity).
« HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies Hypertrophic Cardiomyopathy Recommendations 2011 (Recomendaciones 2011 para Cardiopatía Hipertrófica) »